WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

Triumeq 5 mg/60 mg/30 mg dispersible tablets[1]

Abacavir (as sulfate)/Dolutegravir (as sodium)/Lamivudine
60mg/5mg/30mg dispersible tablet

Triumeq was submitted in 2024 by Viiv Healthcare B.V.. to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the management of HIV/AIDS on 05 March 2024.

Information on the site(s) involved in the manufacture of the product and the APIs is available at the products listing information: https://extranet.who.int/prequal/medicines/ha791

The "Procedure for prequalification of pharmaceutical products[2]" defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the European Medicines Agency (EMA https://www.ema.europa.eu/en/medicines), in line with the "Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities" [3].

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant[4].

[1] Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

[2] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2

[3] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2

[4] https://extranet.who.int/prequal/sites/default/files/document_files/48%20Stability%20data%20SRA%20FPPs_March2016_newtempl.pdf

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

- Do not store above 30°C.
- Store in the original package in order to protect from moisture. Keep the bottle tightly closed. Do not remove the desiccant. Do not swallow the desiccant.
- The shelf-life at this storage condition is 36 months.

Based on the above, the WHOPAR for Triumeq refers for parts 1, 3, 4, 5, 6 and 8 to the previously issued public assessment report as follows:

WHOPAR part		**Reference**[5]
Part 1	Summary for the Public	https://www.ema.europa.eu/en/documents/overview/triumeq-epar-medicine-overview_en.pdf
Part 3	Package Leaflets	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf
Part 4	Summaries Product Characteristics	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf
Part 5	Labelling	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf
Part 6	Discussion	https://www.ema.europa.eu/en/documents/assessment-report/triumeq-epar-public-assessment-report_en.pdf
Part 8	Steps taken following Authorisation	https://www.ema.europa.eu/en/documents/procedural-steps-after/triumeq-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf

Parts 2 and 7 of the WHOPAR for Triumeq are included here.
For products for which the WHO recommended uses differ from those authorized by the reference authority, additionally parts 3a, 4a and 5a are included.

Triumeq contains abacavir (as sulfate), dolutegravir (as sodium) and lamivudine. Its WHO recommended use is for the management of HIV/AIDS.

[5] https://www.ema.europa.eu/en/medicines/human/EPAR/triumeq

Summary of Prequalification Status for Triumeq 5 mg/60 mg/30 mg dispersible tablets

Initial acceptance	**Date**	**Outcome**
Status on PQ list	05 March 2024	listed
Quality	February 2024	MR
PQ: prequalification MR: meets requirements		

The table represents the status of relevant completed activities only.